Compounded Tirzepatide: What It Is and What to Expect
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded tirzepatide is not the same as brand-name products such as Zepbound or Mounjaro and may differ in formulation, purity, and potency.
You have heard tirzepatide works better than semaglutide. You have also heard a lot of different things about compounded versions and whether they are legitimate. This page explains what compounded tirzepatide actually is, how it differs from brand-name tirzepatide, where its regulatory status stands, and what to check if you are considering this path.
What compounded tirzepatide is (and what it isn’t)
Compounded tirzepatide is tirzepatide that has been prepared by a state-licensed compounding pharmacy or an FDA-registered outsourcing facility from active pharmaceutical ingredients (APIs). It is not manufactured by the drug’s maker under an FDA-approved application. The FDA has not reviewed it for safety, effectiveness, or quality[1]. It is not the same product as brand-name tirzepatide, which Eli Lilly and Company sells as Zepbound (for chronic weight management and for obstructive sleep apnea in adults with obesity) and Mounjaro (for type 2 diabetes)[5][6].
Compounding is legal only under specific federal and state pharmacy compounding laws. Compounded tirzepatide became widely available while tirzepatide injection was on the FDA’s drug shortage list, from 2022 until FDA determined the shortage was resolved[2]. Since then, the conditions under which pharmacies may compound it are much narrower, and availability may shift.
The most important point upfront: compounded tirzepatide is not FDA-approved. The clinical trials of tirzepatide studied the brand-name product, not compounded versions. A compounded product has not gone through FDA review the way an approved drug has. This is not a technicality. It is a meaningful distinction that should factor into your decision.
The regulatory framework: why compounded tirzepatide exists
Federal law allows licensed compounders to prepare versions of a drug on the FDA’s drug shortage list if the compounded drug meets certain conditions in federal law[1]. This provision exists so patients can keep getting medication when commercial supply cannot meet demand.
Tirzepatide’s shortage status has already changed. On December 19, 2024, after re-evaluating an earlier decision, the FDA issued a new decision that the tirzepatide injection shortage was resolved[2]. The FDA set end dates for the time it would not take action against compounders over shortage-dependent conditions. After a federal court denied a preliminary injunction on March 5, 2025, in Outsourcing Facilities Association v. FDA, the FDA stated that this period had ended for state-licensed 503A pharmacies. For 503B outsourcing facilities, it ran until March 19, 2025[2]. As of October 2026, FDA’s drug shortage database lists the tirzepatide injection shortage as resolved[3]. The FDA has posted later updates to its compounding policy, most recently dated April 1, 2026; check the FDA page for the current statement[2].
Compounding pharmacies operate under two federal regulatory frameworks:
503A pharmacies are state-licensed traditional compounders that prepare medications based on individual patient prescriptions. State boards of pharmacy have primary responsibility for their day-to-day oversight[1].
503B outsourcing facilities are registered with the FDA and subject to Current Good Manufacturing Practice (CGMP) requirements. They can prepare medications in larger batches and are inspected by the FDA on a risk-based schedule[1][4].
Neither type produces FDA-approved medications. FDA registration (for 503B) is not the same as FDA approval of the product. If you are considering compounded tirzepatide, ask the program which pharmacy prepares it and check that pharmacy’s license yourself.
For more detail on these two pharmacy types and what it means for your medication, see: 503A vs 503B pharmacy explained.
Why people choose compounded tirzepatide over branded versions
The primary reason is cost. Brand-name tirzepatide generally costs more than compounded tirzepatide when paid out of pocket, although manufacturer self-pay programs and insurance coverage can change what you pay. Prices vary by program, product, and dose. We plan to publish current market prices with sources and capture dates; until then, compare the total cost of each option you are quoted.
Compounded tirzepatide often costs less because a compounding pharmacy prepares it from active ingredients rather than the drug’s maker manufacturing it under an FDA-approved application. The lower cost reflects the compounding model, not clinical equivalence. Compounded medications are different products.
The secondary consideration is access. Many insurance plans do not cover weight management medications, and prior authorization requirements can delay or prevent access even when coverage exists. Many programs that offer compounded tirzepatide are cash-pay and do not bill insurance, so you pay the full cost yourself.
The compounding process: how it’s made and what quality depends on
Compounded tirzepatide is prepared by a licensed compounding pharmacist using active pharmaceutical ingredients (APIs), sterile solvents, and containers. The process is similar to how pharmacists have prepared custom medications for individual patients for decades.
What you receive is different from what a pharmaceutical manufacturer produces. A drug maker manufactures under controlled conditions at industrial scale, follows the manufacturing process in its FDA-approved application, and is subject to FDA inspection and review. A compounding pharmacy prepares medication in smaller batches, following state and federal requirements, but without FDA review of the product.
Quality and safety depend significantly on the pharmacy’s practices and oversight. Key things to check include:
State licensure. The pharmacy holds an active license from the state pharmacy board where it operates, and from your state if it ships to you.
Voluntary accreditation. Some compounding pharmacies hold voluntary accreditation, such as PCAB accreditation, now administered by ACHC. Ask whether the pharmacy is accredited and by whom.
Batch testing and certificate of analysis (COA). Ask whether the pharmacy tests each batch for potency, sterility, and purity, and whether it uses an independent lab.
FDA inspection history. For 503B facilities, check FDA’s registered outsourcing facility list and look for FDA Form 483 observations or warning letters related to the product being compounded[4].
Provider oversight. A licensed provider should review your health history and decide whether tirzepatide is clinically appropriate for you before anything is prescribed.
What makes tirzepatide different from semaglutide
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist. The difference is that tirzepatide activates two hormone receptors (GIP and GLP-1), while semaglutide activates only one (GLP-1)[5].
In the SURMOUNT-5 trial, published in 2025, adults with obesity and without type 2 diabetes who took brand-name tirzepatide at the maximum tolerated dose (10 or 15mg weekly) lost an average of 20.2% of body weight at 72 weeks, compared with 13.7% for brand-name semaglutide at its maximum tolerated dose (1.7 or 2.4mg weekly)[7]. This is one reason some providers recommend tirzepatide when appropriate for a patient’s health history. These results describe the FDA-approved products studied, not compounded versions, and they are not a prediction for any individual. Results vary.
Tirzepatide has risks as well as benefits. On the Zepbound label, the most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux. The label carries a boxed warning about thyroid C-cell tumors, and tirzepatide should not be used by people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, or people with a known serious allergy to tirzepatide[5]. Compounded tirzepatide has not been evaluated by the FDA, so label information describes the brand-name product.
For a detailed comparison of the two medications, see: Tirzepatide vs semaglutide: complete comparison.
What a proper weight loss program should include
Transformation Health does not sell medication or set prices. There is no standard bundle, and prices vary by program and dose. When you compare programs, look for each of these line items and note whether it is included, billed separately, or not offered.
The medication. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy and, at most telehealth programs, shipped to you. Check whether syringes, needles, and other supplies are included, and ask which pharmacy prepares it.
Provider care. At most telehealth programs, a licensed provider reviews your health history and current medications, decides whether tirzepatide is clinically appropriate, and follows up during treatment. Ask whether follow-up visits cost extra.
Lab work. Some programs require blood work before or during treatment. Ask whether it is included, where it is drawn, and whether it is billed to you or your insurance.
Coaching or nutrition support. Some programs include nutrition or lifestyle coaching; many do not. If it matters to you, ask what it involves and whether it costs extra.
Clear terms. Look for separate membership fees, dose-based price increases, minimum commitments, prepay requirements, and how cancellation works.
- Usually injected once weekly
- Price often rises with the dose
- Ask what the fee covers: labs, visits, supplies
- Not FDA-approved
- Usually injected once weekly
- GIP and GLP-1 receptor agonist
- Ask what the fee covers: labs, visits, supplies
- Not FDA-approved
- Usually taken daily
- Not the same as FDA-approved semaglutide tablets
- Ask what the fee covers: labs, visits, shipping
- Not FDA-approved
Transformation Health does not accept payment from providers. How we make money.
Who qualifies for compounded tirzepatide
A licensed provider decides whether tirzepatide is appropriate based on your health history. Programs set their own criteria.
BMI criteria. Many programs use criteria similar to the brand-name label. Zepbound is approved, along with a reduced-calorie diet and increased physical activity, for adults with obesity, or adults with overweight and at least one weight-related condition. In the main trial that supported that approval, enrolled adults had a BMI of 30 or higher, or a BMI of 27 to under 30 with at least one weight-related condition such as high blood pressure, abnormal cholesterol, obstructive sleep apnea, or heart disease[5].
Health history. The provider should review your current medications, medical conditions, and any reasons GLP-1 medication may not be appropriate for you. Some medical situations make tirzepatide inappropriate.
A provider may decide it is not appropriate. Even if your BMI meets a program’s threshold, a provider may decide tirzepatide is not right for your health situation. This is a medical decision, not an automatic approval based on weight alone.
State rules. Telehealth prescribing rules differ by state. Ask the program how it handles your state.
How the process should work
Step 1: Health history
At most telehealth programs, you fill out a form covering your health history, current medications, and goals.
Step 2: Provider review
A licensed provider reviews your information and decides whether compounded tirzepatide is clinically appropriate for you.
Step 3: Pharmacy preparation
If a provider prescribes it, a state-licensed compounding pharmacy prepares the medication. Ask which pharmacy the program uses.
Step 4: Delivery and follow-up
The medication usually arrives by mail. A proper program includes follow-up with a licensed provider while you take it.
Important limitations to understand
Not FDA-approved. Compounded tirzepatide has not been reviewed by the FDA for safety, effectiveness, or quality[1]. This differs from brand-name tirzepatide, which went through FDA review. The FDA has not confirmed whether compounded tirzepatide is safe or effective at the dose you receive.
Different product. Compounded tirzepatide is not the same as brand-name tirzepatide. Formulation, purity, and potency may differ. You cannot assume compounded tirzepatide will produce the same results as Zepbound or Mounjaro, even though it contains tirzepatide.
Regulatory status can change. Tirzepatide is no longer on the FDA’s drug shortage list, and the FDA’s enforcement discretion periods for shortage-based compounding ended in 2025[2]. Compounding of tirzepatide depends on federal and state pharmacy law and FDA policy. Availability cannot be guaranteed.
Individual results vary. Weight loss is not guaranteed. The amount of weight you lose depends on many factors including your starting weight, age, metabolism, adherence to the medication, diet, exercise, stress, sleep, and overall health. Trial results describe study participants and are not a prediction for any individual. A licensed provider can help you understand what a realistic outcome looks like for your situation.
Dosing: how compounded tirzepatide is prescribed
Tirzepatide is given as a once-weekly injection under the skin. On the Zepbound label, dosing starts at 2.5mg once weekly for 4 weeks and increases in 2.5mg steps at least 4 weeks apart, up to a maintenance dose of 5mg, 10mg, or 15mg[5]. The dosing schedule for a compounded product is set by the prescriber and has not been reviewed by the FDA.
Compounded formulations are often prepared at specific concentrations (mg/mL), which means you measure doses in units using an insulin syringe. The prescriber and pharmacy should give you clear instructions on how to measure and give your specific dose.
For a detailed guide on unit conversions and standard concentrations, see: Tirzepatide dosing in units.
The bigger picture: medication as a bridge
Tirzepatide reduces appetite and slows digestion[5]. It quiets the constant signal your brain receives to eat more. For many people, this creates the mental space to build better eating habits and change the relationship with food.
Plan for the long term. Zepbound is approved to reduce excess body weight and maintain that reduction long term[5]. In the SURMOUNT-4 trial, published in 2024, people who switched from brand-name tirzepatide to placebo regained a substantial share of the weight they had lost over the following year, while those who continued treatment maintained their results on average[8]. Some people step down to a lower dose, and some eventually stop, but stopping often leads to regain, so any change should be planned with your prescriber. Habits built while on the medication still matter either way.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16.)
[2] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)
[3] U.S. Food and Drug Administration. “FDA Drug Shortages: Tirzepatide Injection.” Status: Resolved. Accessed 2026-10-16. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=r
[4] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16.)
[5] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[6] U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
[7] Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” NEJM. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[8] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded tirzepatide is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded tirzepatide is not the same as brand-name products such as Zepbound or Mounjaro and may differ in formulation, purity, and potency. Clinical trial data on this page (SURMOUNT-5, SURMOUNT-4, and the Zepbound label studies) applies to the brand-name products studied. Results vary. Trial results describe study participants and are not a prediction for any individual. Availability of compounded tirzepatide depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by Eli Lilly and Company. Transformation Health does not accept payment from providers. How we make money.